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OBJECTIVE—Single nucleotide polymorphisms (SNPs) in the
P2 promoter region of HNF4A were originally shown to be
associated with predisposition for type 2 diabetes in Finnish,
Ashkenazi, and, more recently, Scandinavian populations, but
they generated conﬂicting results in additional populations. We
aimed to investigate whether data from a large-scale mapping
approach would replicate this association in novel Ashkenazi
samples and in U.K. populations and whether these data would
allow us to reﬁne the association signal.
RESEARCH DESIGN AND METHODS—Using a dense link-
age disequilibrium map of 20q, we selected SNPs from a 10-Mb
interval centered on HNF4A. In a staged approach, we ﬁrst typed
4,608 SNPs in case-control populations from four U.K. popula-
tions and an Ashkenazi population (n  2,516). In phase 2, a
subset of 763 SNPs was genotyped in 2,513 additional samples
from the same populations.
RESULTS—Combined analysis of both phases demonstrated
association between HNF4A P2 SNPs (rs1884613 and rs2144908)
and type 2 diabetes in the Ashkenazim (n  991; P  1.6  10
6).
Importantly, these associations are signiﬁcant in a subset of
Ashkenazi samples (n  531) not previously tested for associa-
tion with P2 SNPs (odds ratio [OR] 1.7; P  0.002), thus
providing replication within the Ashkenazim. In the U.K. popu-
lations, this association was not signiﬁcant (n  4,022; P  0.5),
and the estimate for the OR was much smaller (OR 1.04; [95%CI
0.91–1.19]).
CONCLUSIONS—These data indicate that the risk conferred by
HNF4A P2 is signiﬁcantly different between U.K. and Ashkenazi
populations (P  0.00007), suggesting that the underlying causal
variant remains unidentiﬁed. Interactions with other genetic or
environmental factors may also contribute to this difference in
risk between populations. Diabetes 57:3161–3165, 2008
T
he presence of type 2 diabetes susceptibility
genes on chromosome 20 has been suggested by
linkage scans in several populations. The 20q12–
q13 region (Online Mendelian Inheritance in Man
[OMIM] 603694) is the best replicated and harbors the
gene HNF4A, mutations that lead to type 1 maturity-onset
diabetes of the young (OMIM 125850). Evidence for asso-
ciation between SNPs in the -cell P2 promoter region of
HNF4A has been recognized in Finnish (1) and Ashkenazi
(2) populations, with data suggesting that the HNF4A P2
SNPs (or variants in strong linkage disequilibrium with
them) contribute to the linkage signal on chromosome 20q
(1,2). Association with HNF4A promoter SNPs has been
replicated in some (3–7) but not all (8–12) populations
tested. In other populations, there was evidence for asso-
ciation with SNPs or haplotypes in the HNF4A region
other than the P2 SNPs (10,13–15). More recently, the
association between HNF4A promoter SNPs and type 2
diabetes has been conﬁrmed in Scandinavians but not in a
broader meta-analysis with additional populations (16),
suggesting that P2 SNPs confer varying risk effects in
different populations, possibly due to the underlying
causal variant not having been identiﬁed. We investigated
a 10-Mb interval (38.1–48.2 Mb National Center for Bio-
technology Information build 35) centered around
HNF4A, including genotypes from 4,608 nonredundant
(r
2  1) SNPs (one SNP per 2 Kb, on average) in ﬁve type
2 diabetic case-control populations, to evaluate whether
we could conﬁrm and reﬁne the association signal in
Ashkenazim and whether this association was also present
in U.K. populations. We were also interested in assessing
whether there was evidence for additional association
signals within this broader interval. We tested an Ash-
kenazi type 2 diabetes case-control study (n  998),
including novel samples (n  531) not previously tested
for linkage or association with HNF4A P2 SNPs (2); two
U.K. population-based case-control studies where linkage
and association studies with HNF4A P2 had not be carried
out (n  2,189); and two additional U.K. case-control
collections (n  1,842), with one enriched for earlier-onset
type 2 diabetes where linkage studies had not been done
but that showed suggestive association with HNF4A P2
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DIABETES, VOL. 57, NOVEMBER 2008 3161SNPs (4) and one that included samples where, despite no
evidence of linkage to chromosome 20q, association of
HNF4A P2 SNPs with type 2 diabetes risk had previously
been suggested (4,17).
RESEARCH DESIGN AND METHODS
Populations
Cambridgeshire case-control study. The population-based Cambridgeshire
case-control cohort consisted of randomly selected, unrelated patients with
type 2 diabetes (n  555) and matched, unrelated control subjects (n  541)
(18).
European Prospective Investigation of Cancer-Norfolk. From this pop-
ulation-based cohort study of Norfolk, U.K., 354 type 2 diabetic cases and 739
unrelated control subjects were used in this study (19,20).
Young-onset type 2 diabetes patients from Exeter. From this consecu-
tive-case series of unrelated patients with type 2 diabetes diagnosed before 45
years of age from North and East Devon (21,22) and sex-matched control
subjects from parents in the Exeter Family (22,23), we included 414 case and
425 control subjects in this study.
Diabetes U.K. Warren 2 Repository. The Warren 2 Repository index case
subjects (all Europid) passing all the stringent genome scan criteria of the
Warren 2 Repository, as described (17), totaled 528 probands from 573
families. The 475 control subjects came from the European Collection of Cell
Cultures (ECACC) Human Control Resource.
Ashkenazi case-control study sample. The Ashkenazi case-control study
comprised of 143 cases from multiplex-affected sibships ascertained for
published genome scan (24) and 393 newly ascertained unrelated cases.
Control samples are 149 unrelated subjects with no personal or ﬁrst-degree
family history of type 2 diabetes and 313 additional unrelated samples from
the National Laboratory for the Genetics of Israeli Populations at Tel Aviv
University, Tel Aviv, Israel. Of the control subjects, 138 were novel.
For this study, each of the U.K. populations was randomly subdivided into
two halves and used in either phase 1 or phase 2 of the study. At the onset of
the study, many of the novel Ashkenazi samples were not available for testing;
consequently, 155 cases included in phase 1 were novel, whereas all 238 cases
included in phase two were novel. Of the 138 novel control subjects, 137 were
from phase 2. Ethics permission for all studies was granted by the appropriate
local research ethics committees, and study participants provided informed
consent.
Study design. We applied a two-stage design; in phase 1, we genotyped 934
type 2 diabetic patients and 1,120 control subjects from the four U.K.
populations and 298 type 2 diabetic patients and 164 control subjects from the
Ashkenazi population. Single-SNP associations within the U.K. populations
(collectively referred to as UK4) were performed in a joint analysis including
a term for study. The Ashkenazi data were analyzed independently. Phase 2
included 917 type 2 diabetic patients and 1,060 control subjects from the U.K.
and 238 type 2 diabetic patients and 298 control subjects from the Ashkenazi
population and tested a subset of SNPs tested in phase 1. Results from phase
1 and 2 were combined in joint analysis. Phase 2 in the Ashkenazi set includes
control subjects previously tested for association with HNF4A P2 SNPs (2)
and, thus, cannot be considered replication. To obtain independent evidence
of replication, we analyzed results from the 531 novel Ashkenazi samples
separately. In this set, we conducted permutation testing (10,000 permuta-
tions) to obtain empirical P values.
Genotyping. Based on a dense linkage disequilibrium map of chr20 (25,26),
which included a 10-Mb region (38.1–48.2 Mb National Center for Biotechnol-
ogy Information build 35) centered on HNF4A, we performed pairwise linkage
disequilibrium (LD) analysis on all 5,324 SNP markers with a minor allele
frequency (MAF) 4% (Centre d’Etude du Polymorphisme Humain panel) and
excluded SNPs with an r
2 of 1. This identiﬁed 4,608 SNPs (one SNP per 2 Kb,
on average) for genotyping in phase 1, of which 763 were retested in phase 2
on additional samples. By design, the 4,608 SNPs tagged all variation with
MAF 4% in this region in HapMap phase 1 data. SNPs were assayed with
Illumina’s Golden Gate assay as described elsewhere (25,27), and standard
sample and genotyping quality controls were applied (see supplementary
information, available in an online appendix at http.dx.doi/10.2337/db08-0719).
Statistical analysis. All analyses were conducted using Stata/SE 9.2 for
windows or Unix (Stata Corporation, College Station, TX). Genotype frequen-
cies were tested for Hardy-Weinberg equilibrium using a 
2 goodness-of-ﬁt test
in control and case subjects, separately. For each SNP, association with type
2 diabetes was tested using an additive model on 1 d.f. The equality of allele
frequencies between phases was tested using large-sample statistics in control
and case subjects, separately.
In all joint analyses, when no signiﬁcant heterogeneity (P  0.05) was
detected (between populations and between phases), an odds ratio (OR) using
the Mantel-Haenszel method was estimated. However, when signiﬁcant het-
erogeneity was detected, a random-effects meta-analysis was applied. Addi-
tional details regarding the study design and methods are available in the
online appendix supplementary table.
RESULTS
Phase 1 results in UK4 for all SNPs that survived quality
control are shown in Fig. 1A. SNPs with nominally signif-
icant results (P  0.05, unadjusted for multiple testing) in
the Ashkenazi population are also shown. There was very
modest overlap between the nominal signiﬁcant results in
UK4 and Ashkenazim. To avoid both false-positive associ-
ation claims (type I error) and false-negative claims (type
II error), we selected all SNPs with P  0.15 in the UK4 to
test in a further set of independent samples in phase 2 of
the study. Additional SNPs with P  0.01 in Ashkenazim
not included in the previous selection were also added. In
total, 763 SNPs were tested in phase 2 on an additional 916
type 2 diabetic case and 1,059 control subjects in the U.K.
population and 238 case and 298 control subjects in the
Ashkenazi population.
In the Ashkenazim, there was signiﬁcant association
between SNPs in the HNF4A P2 region, rs1884613 (P 
6.8  10
7) and rs2144908 (P  1.3  10
6), and type 2
diabetes (Fig. 1B); 10 SNPs in the GDAP1L1 gene (P 
5.3  10
4, [supplementary Table 2]) were also associated
with type 2 diabetes. Importantly, the association with
SNP rs1884613 (OR 1.70; P  0.0014 and empirical P 
0.0012) is independently replicated (Table 1) (similar
TABLE 1
Genotype counts for HNF4A P2 SNP rs1884613 in each U.K. and Ashkenazi population
Control subjects Case subjects OR 95% CI P
n 11 12 22 11 12 22 — — —
ASH (new) 90 (65.69) 41 (29.93) 6 (4.38) 200 (51.81) 142 (36.79) 44 (11.40) 1.7014 1.23–2.36 0.0014*
ASH (old) 217 (65.69) 88 (27.41) 16 (4.98) 76 (54.68) 57 (41.01) 6 (4.32) 1.5581 1.06–2.30 0.0248
CCC 381 (72.16) 138 (26.14) 9 (1.70) 375 (68.93) 156 (28.68) 13 (2.39) 1.1596 0.92–1.47 0.2201
Exeter 147 (71.71) 55 (26.83) 3 (1.46) 152 (76.38) 44 (22.11) 3 (1.51) 0.8173 0.54–1.23 0.3314
EPIC-Norfolk 506 (68.94) 209 (28.47) 19 (2.59) 239 (67.51) 108 (30.51) 7 (1.98) 1.0331 0.81–1.32 0.7937
W2 318 (71.30) 110 (24.66) 18 (4.04) 338 (68.70) 144 (29.27) 10 (2.03) 1.0218 0.80–1.30 0.861
Meta-analysis 1,659 (69.97) 641 (27.04) 71 (2.99) 1,380 (65.28) 651 (30.79) 83 (3.93) 1.1394 0.90–1.45 0.2833
Data are genotype counts (frequencies) unless otherwise indicated. Genotype counts (and frequencies) are shown for those homozygous for
the common allele (n  11), heterozygous (n  12), and homozygous for the minor allele (n  22). ORs, 95% CIs, and P values are based
on an additive model. For SNP rs1884613, there is a lower call rate for Exeter samples. *P 0.01. ASH (new), novel Ashkenazi samples not
previously tested for association (138 control and 393 case subjects); ASH (old), Ashkenazi samples overlapping with those in the original
report (ref. 2) (324 control and 143 case subjects); CCC, Cambridgeshire study; EPIC-Norfolk, European Prospective Investigation of
Cancer-Norfolk; W2, Warren 2 Repository.
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FIG. 1. Single SNP association results. A: Phase 1 results in UK4 (all results) and nominal signiﬁcant association results in Ashkenazi (P < 0.05).
B: Joint analysis of phase 1 and 2 results in UK4 (all results) and nominally signiﬁcant association results in Ashkenazi (P < 0.05). log10 of the
unadjusted P value is shown on the y-axis, whereas chromosome coordinates are shown on the x-axis. Dashed line represents nominal signiﬁcance
(P  0.05). ASH, Ashkenazi data; ASH–HNF4A P2, results for two HNF4A P2 SNPs (rs1884613 and rs2144908) in the Ashkenazim. Genes with
most signiﬁcant results are shown as black bars; location of HNF4A on the chromosome is shown as gray bars.
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DIABETES, VOL. 57, NOVEMBER 2008 3163results were obtained for rs2144908) in the subset of novel
Ashkenazi samples (393 case and 138 control subjects). In
contrast, of the 16 PREX1 SNPs with signiﬁcant results in
phase 1 (P  0.01) in the joint analysis, none achieved
equivalent signiﬁcance (Fig. 1A and B). There was also no
evidence for association with other SNPs (rs2425637,
rs2425639, rs2425640, rs6130609, and rs745975; P  0.2)
mapping to the coding sequence or P1 promoter of HNF4A
(data not shown). In contrast with the Ashkenazi data, in
UK4, there was no evidence of stronger association based
on the joint analysis compared with the results from phase
1 alone (Fig. 1A and B and supplementary Table 3);
furthermore, none of the results would survive any kind of
multiple-testing correction.
We used log-likelihood ratio tests to assess whether
SNPs rs1884613 and rs2144908 explained all of the ob-
served associations with type 2 diabetes in this region. The
correlation between SNPs rs1884613 and rs2144908 is very
high (r
2  0.99); therefore, we cannot separate their
effects on type 2 diabetes risk. We consecutively added
the other SNPs in this region in a log-additive form to a
model containing these SNPs (1 d.f., assuming no dom-
inance at the test locus). This analysis demonstrated
that none of the other SNPs in this region of high LD
improved the model containing just one of either
rs1884613 or rs2144908, and it indicates that no additional
genotyped SNP is independently contributing to type 2
diabetes risk (data not shown). The reciprocal analysis
showed that addition of either rs1884613 or rs2144908
improved all models containing any of the other SNPs.
Repeating this analysis with phase 1 data (higher SNP
density, although on a smaller sample size; data not
shown) conﬁrms these results and suggests that no other
genotyped SNP in this region is independently associated
with type 2 diabetes risk.
DISCUSSION
This study provides clear evidence for association of
HNF4A P2 promoter SNPs with type 2 diabetes in the
Ashkenazim. Importantly, these results are replicated in
the subset of novel samples (393 case and 138 control
subjects) that are independent of those used in the original
report (2), with a point estimate of OR 1.70 (P  0.0014)
for rs1884613 (Table 1). However, despite the relatively
high density of SNPs used to span the 10-Mb candidate
interval (1 SNP/2 Kb on average), we were unable to reﬁne
the association signal beyond the two originally associated
SNPs (rs1884613 and rs2144908) in the Ashkenazim. Thus,
further ﬁne-mapping in this region will be required to
identify the underlying causal variant. In contrast, in UK4,
this association result could not be replicated (OR 1.04;
P  0.5). Furthermore, the CIs for the ORs in UK4 and the
Ashkenazim did not overlap (supplementary Table 2),
showing that the risk of P2 SNPs on type 2 diabetes in
these two groups is signiﬁcantly different (P  0.00007).
Independent analysis of each U.K. population also did not
provide evidence for association of HNF4A P2 SNPs and
diabetes risk in any of the individual populations (supple-
mentary Table 4).
Within the U.K., the previously reported effect size for
nominally associating SNPs (rs4810424 and rs2144908)
was small (OR 1.09–1.13) (4), with an MAF of 16%, 	 0.05,
and a sample size of 4,022; our U.K. populations were
underpowered to detect such effects (power 54%), which
could underlie our lack of association. Importantly, both
the current and previously reported CIs for the effect size
in the U.K. (4) do not overlap with those in the Ashkena-
zim, suggesting population-speciﬁc effects. We observed
signiﬁcant heterogeneity of effects at these SNPs (P 
0.0001) between U.K. and Ashkenazim populations by
comparing logistic regression models, with and without a
genotype  study interaction term using a likelihood ratio
test.
Allele frequency and Fst values across the region sug-
gested that there was no evidence of signiﬁcant genetic
distance at these loci (supplementary information). Fur-
thermore, LD plots and unit maps across this region
(supplementary information) also demonstrated that,
overall, the magnitude of LD was not materially different
between Ashkenazi and U.K. populations and was unlikely
to signiﬁcantly contribute to divergent results. Thus, our
data suggest that if HNF4A P2 SNPs are a risk factor for
type 2 diabetes in U.K. European populations, the risk they
confer is considerably smaller than that which they impart
on the Ashkenazi population, which is consistent with
linkage having been observed in Ashkenazim (24) but not
in U.K. samples (17) and with other, more recent results
(16).
This result provides further support for the involvement
of HNF4A P2 SNPs (or others in high LD) in conferring
risk of type 2 diabetes in Ashkenazim and has important
wider implications because it demonstrates the beneﬁt of
performing replication testing in samples that are re-
cruited from the same population sampling frame as those
used in the exploratory early stages of an association
study. Population-speciﬁc effects will have a signiﬁcant
impact in the interpretation of results from replication
studies.
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